JP2022522328A5 - - Google Patents
Info
- Publication number
- JP2022522328A5 JP2022522328A5 JP2021540127A JP2021540127A JP2022522328A5 JP 2022522328 A5 JP2022522328 A5 JP 2022522328A5 JP 2021540127 A JP2021540127 A JP 2021540127A JP 2021540127 A JP2021540127 A JP 2021540127A JP 2022522328 A5 JP2022522328 A5 JP 2022522328A5
- Authority
- JP
- Japan
- Prior art keywords
- combination according
- once
- administered
- cancer
- week
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962811303P | 2019-02-27 | 2019-02-27 | |
| US62/811,303 | 2019-02-27 | ||
| PCT/US2020/020171 WO2020176772A1 (en) | 2019-02-27 | 2020-02-27 | Administration of sumo-activating enzyme inhibitor and checkpoint inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022522328A JP2022522328A (ja) | 2022-04-18 |
| JP2022522328A5 true JP2022522328A5 (https=) | 2023-03-06 |
| JP7539896B2 JP7539896B2 (ja) | 2024-08-26 |
Family
ID=72238984
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021540127A Active JP7539896B2 (ja) | 2019-02-27 | 2020-02-27 | Ｓｕｍｏ活性化酵素阻害剤及びチェックポイント阻害剤の投与 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US12419890B2 (https=) |
| EP (1) | EP3930719B1 (https=) |
| JP (1) | JP7539896B2 (https=) |
| KR (1) | KR20210131316A (https=) |
| CN (1) | CN113473989B (https=) |
| AU (1) | AU2020228385A1 (https=) |
| BR (1) | BR112021016795A8 (https=) |
| CA (1) | CA3128521A1 (https=) |
| MX (1) | MX2021010176A (https=) |
| TW (1) | TW202045175A (https=) |
| WO (1) | WO2020176772A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2021000349A (es) | 2018-07-09 | 2021-05-14 | Takeda Pharmaceuticals Co | Administracion de un inhibidor de la enzima activadora de sumo y anticuerpos anti-cd20. |
| CA3128521A1 (en) | 2019-02-27 | 2020-09-03 | Millennium Pharmaceuticals, Inc. | Administration of sumo-activating enzyme inhibitor and checkpoint inhibitors |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20150071948A1 (en) * | 2003-09-26 | 2015-03-12 | Gregory Alan Lazar | Novel immunoglobulin variants |
| AU2005235422B2 (en) * | 2004-04-22 | 2011-08-11 | Boehringer Ingelheim International Gmbh | New pharmaceutical compositions for the treatment of sexual disorders II |
| BRPI0516132A (pt) | 2004-10-07 | 2007-12-04 | Vitae Pharmaceuticals Inc | compostos, composição destes, método de antagonização de uma ou mais proteases aspárticas e método para tratar ou melhorar um distúrbio mediado por protease aspártica |
| ES2542884T3 (es) * | 2008-09-23 | 2015-08-12 | Rigel Pharmaceuticals, Inc. | Inhibidores de JAK de carbamato tricíclico |
| WO2010044892A1 (en) | 2008-10-17 | 2010-04-22 | President And Fellows Of Harvard College | Diagnostic method based on large scale identification of post-translational modification of proteins |
| EP3255060A1 (en) | 2008-12-09 | 2017-12-13 | F. Hoffmann-La Roche AG | Anti-pd-l1 antibodies and their use to enhance t-cell function |
| WO2012159782A1 (en) | 2011-05-24 | 2012-11-29 | Asociación Centro De Investigación Cooperativa En Biociencias-Cic Biogune | High affinity sumo traps |
| CN105492429A (zh) | 2013-07-02 | 2016-04-13 | 米伦纽姆医药公司 | Sumo活化酶的杂芳基抑制剂 |
| WO2015064532A1 (ja) * | 2013-10-30 | 2015-05-07 | 第一三共株式会社 | モルホリン化合物 |
| IL292510A (en) | 2013-11-05 | 2022-06-01 | Cognate Bioservices Inc | Combinations of checkpoint inhibitors and therapeutics to treat cancer |
| BR112016030787B1 (pt) | 2014-07-01 | 2022-12-20 | Takeda Pharmaceutical Company Limited | Entidade química, composição farmacêutica e seu uso |
| TWI874834B (zh) * | 2014-12-18 | 2025-03-01 | 瑞士商赫孚孟拉羅股份公司 | 四氫-吡啶并[3,4-b]吲哚雌激素受體調節劑及其用途 |
| NZ738406A (en) * | 2015-06-11 | 2023-04-28 | Bionomics Ltd | Pharmaceutical combination of a tubulin polymerization inhibitor with an inhibitor of pd-l1, pd-1, or ctla-4 and uses and compositions thereof |
| US20190054090A1 (en) * | 2015-10-01 | 2019-02-21 | Gilead Sciences, Inc. | Combination of a btk inhibitor and a checkpoint inhibitor for treating cancers |
| KR20180105685A (ko) | 2016-02-08 | 2018-09-28 | 비욘드스프링 파마수티컬스, 인코포레이티드. | 투카레솔 또는 이의 유사체를 함유하는 조성물 |
| WO2018154529A1 (en) | 2017-02-27 | 2018-08-30 | Novartis Ag | Dosing schedule for a combination of ceritinib and an anti-pd-1 antibody molecule |
| MX2019012431A (es) | 2017-04-21 | 2020-08-03 | Ikena Oncology Inc | Inhibidores del receptor de hidrocarburos de arilo (ahr) de indol y usos de los mismos. |
| CA3128521A1 (en) | 2019-02-27 | 2020-09-03 | Millennium Pharmaceuticals, Inc. | Administration of sumo-activating enzyme inhibitor and checkpoint inhibitors |
-
2020
- 2020-02-27 CA CA3128521A patent/CA3128521A1/en active Pending
- 2020-02-27 KR KR1020217023362A patent/KR20210131316A/ko not_active Withdrawn
- 2020-02-27 WO PCT/US2020/020171 patent/WO2020176772A1/en not_active Ceased
- 2020-02-27 US US17/433,042 patent/US12419890B2/en active Active
- 2020-02-27 CN CN202080016443.3A patent/CN113473989B/zh active Active
- 2020-02-27 TW TW109106512A patent/TW202045175A/zh unknown
- 2020-02-27 EP EP20762132.7A patent/EP3930719B1/en active Active
- 2020-02-27 BR BR112021016795A patent/BR112021016795A8/pt unknown
- 2020-02-27 JP JP2021540127A patent/JP7539896B2/ja active Active
- 2020-02-27 AU AU2020228385A patent/AU2020228385A1/en not_active Abandoned
- 2020-02-27 MX MX2021010176A patent/MX2021010176A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102105152B (zh) | 包含cdks抑制剂和抗肿瘤剂的治疗组合 | |
| CN111065411B (zh) | Pd-1抗体和vegfr抑制剂联合治疗小细胞肺癌的用途 | |
| JP2023534009A5 (https=) | ||
| CN109985237B (zh) | 一种治疗结直肠癌的药物组合物及其应用 | |
| CN102753176A (zh) | 含有cdc7抑制剂和抗癌药的治疗组合物 | |
| JP2022522328A5 (https=) | ||
| WO2022111714A1 (zh) | 用于治疗pik3ca突变癌症的组合疗法 | |
| JP2024506684A5 (https=) | ||
| JP2022501332A5 (https=) | ||
| Ocvirk et al. | Management of cutaneous side effects of cetuximab therapy with vitamin K1 creme | |
| CN111246881B (zh) | Pd-1抗体用于治疗肿瘤的用途 | |
| JP2024521105A5 (https=) | ||
| TW200306185A (en) | Combinations comprising EPOTHILONES and anti-metabolites | |
| JP2023531090A5 (https=) | ||
| JP2023500480A5 (https=) | ||
| JP2022547061A5 (https=) | ||
| JP2022522328A (ja) | Ｓｕｍｏ活性化酵素阻害剤及びチェックポイント阻害剤の投与 | |
| CN1330308C (zh) | 含有4－吡啶基甲基酞嗪的联合产品及其应用 | |
| RU2021123498A (ru) | Введение ингибитора sumo-активирующего фермента и ингибиторов контрольных точек | |
| TWI671072B (zh) | 曲氟尿苷(trifluridine)/替匹拉希(tipiracil)鹽酸鹽、抗腫瘤鉑錯合物及免疫檢查點調節子之間的新穎組合 | |
| WO2019096233A1 (zh) | 免疫治疗剂、核苷类抗代谢物和铂类联合在制备治疗肿瘤的药物中的用途 | |
| CN113491769A (zh) | 药物联合 | |
| EP3733202A1 (en) | Use of combined treatment of pd-1 antibody and apatinib for treating triple negative breast cancer | |
| CN110680919A (zh) | Cdk4/6抑制剂联合免疫治疗在制备治疗肿瘤的药物的用途 | |
| TW202241421A (zh) | 菸鹼醯胺及含有其的組合物的製藥用途 |